JWH-371

JWH-371

Legal status
Legal status	CA: Schedule II UK: Class B
Identifiers
IUPAC name [5-(4-butylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
PubChem CID	44418349
ChemSpider	23277927 Y
Chemical and physical data
Formula	C30H33NO
Molar mass	423.600 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCCCN1C=C(C=C1C2=CC=C(C=C2)CCCC)C(=O)C3=CC=CC4=CC=CC=C43
InChI InChI=1S/C30H33NO/c1-3-5-9-20-31-22-26(21-29(31)25-18-16-23(17-19-25)11-6-4-2)30(32)28-15-10-13-24-12-7-8-14-27(24)28/h7-8,10,12-19,21-22H,3-6,9,11,20H2,1-2H3 Y Key:PKNGYYSGLHBRGC-UHFFFAOYSA-N Y

JWH-371 ([5-(4-butylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone) is a synthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of the CB₁ (K_i = 42 ± 1nM) and CB₂ (K_i = 64 ± 2nM) receptors, binding ~1.5 times stronger to the CB₁ receptor than the CB₂ receptor. JWH-371 was first synthesized in 2006 by John W. Huffman and colleagues to examine the nature of ligand binding to the CB₁ receptor.

Legality

In the United States JWH-371 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-371.

In Canada, JWH-371 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under the Controlled Drugs and Substances Act.

In the United Kingdom, JWH-371 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under the Misuse of Drugs Act 1971.

See also

• List of JWH cannabinoids
• Synthetic cannabinoid